Eli Lilly Signs $2.75 Billion AI Drug Discovery Deal with Insilico Medicine
Eli Lilly has inked a deal worth up to $2.75 billion with AI pharma firm Insilico Medicine to develop and commercialize AI-discovered oral drugs globally.
Eli Lilly has inked a deal worth up to $2.75 billion with AI pharma firm Insilico Medicine to develop and commercialize AI-discovered oral drugs globally.
NVIDIA and Eli Lilly have announced a landmark $1 billion partnership to create a co-innovation lab focused on using AI to revolutionize drug discovery and pharmaceutical manufacturing, aiming to drastically reduce development timelines.